DOP2013000090A - “HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-{2,4- BIS(TRIFUOROMETIL)-5,8-DI-HIDROPIRIDO{3,4-d} PIRIMIDIN-7 (6H)-IL}-4-OXOBUTIL}-5,5-DIFLUORO-PIRIDIN-2-ONA” - Google Patents

“HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-{2,4- BIS(TRIFUOROMETIL)-5,8-DI-HIDROPIRIDO{3,4-d} PIRIMIDIN-7 (6H)-IL}-4-OXOBUTIL}-5,5-DIFLUORO-PIRIDIN-2-ONA”

Info

Publication number
DOP2013000090A
DOP2013000090A DO2013000090A DO2013000090A DOP2013000090A DO P2013000090 A DOP2013000090 A DO P2013000090A DO 2013000090 A DO2013000090 A DO 2013000090A DO 2013000090 A DO2013000090 A DO 2013000090A DO P2013000090 A DOP2013000090 A DO P2013000090A
Authority
DO
Dominican Republic
Prior art keywords
oxobutyl
pyrimidin
bis
amino
trifuomethyl
Prior art date
Application number
DO2013000090A
Other languages
English (en)
Inventor
Min Yun Jung
Sook Park Ki
Kim Bong-Chan
Young Kim Kyu
Hye Lee Ji
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45995015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000090(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of DOP2013000090A publication Critical patent/DOP2013000090A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se refiere al 1,5 hidrato de tartrato de 1-{(2S)-2-amino-4-[2,4-bis(trifluorometil)-5,8-dihidropirido[3,4-d]pirimidin-7(6H)-il]-4-oxobutil}-5,5-difluoropiperidin-2-ona, un proceso para prepararlo, y una composición farmacéutica para inhibir la DPP-IV, que comprende dicho compuesto como componente activo.
DO2013000090A 2010-11-01 2013-04-22 “HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-{2,4- BIS(TRIFUOROMETIL)-5,8-DI-HIDROPIRIDO{3,4-d} PIRIMIDIN-7 (6H)-IL}-4-OXOBUTIL}-5,5-DIFLUORO-PIRIDIN-2-ONA” DOP2013000090A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20100107868 2010-11-01

Publications (1)

Publication Number Publication Date
DOP2013000090A true DOP2013000090A (es) 2018-06-30

Family

ID=45995015

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000090A DOP2013000090A (es) 2010-11-01 2013-04-22 “HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-{2,4- BIS(TRIFUOROMETIL)-5,8-DI-HIDROPIRIDO{3,4-d} PIRIMIDIN-7 (6H)-IL}-4-OXOBUTIL}-5,5-DIFLUORO-PIRIDIN-2-ONA”

Country Status (29)

Country Link
US (1) US8859567B2 (es)
EP (1) EP2635580B1 (es)
JP (1) JP6193762B2 (es)
KR (1) KR101446789B1 (es)
CN (1) CN103189375B (es)
AP (1) AP3287A (es)
AR (1) AR083591A1 (es)
AU (1) AU2011324253B2 (es)
BR (1) BR112013010586A2 (es)
CA (1) CA2814357C (es)
CL (1) CL2013001137A1 (es)
CO (1) CO6710945A2 (es)
DO (1) DOP2013000090A (es)
EA (1) EA024679B1 (es)
EC (1) ECSP13012599A (es)
GE (1) GEP20156218B (es)
IL (1) IL225808A (es)
MA (1) MA34625B1 (es)
MX (1) MX341584B (es)
MY (1) MY156428A (es)
NZ (1) NZ609644A (es)
PE (3) PE20240220A1 (es)
PH (1) PH12013500685A1 (es)
SG (1) SG189931A1 (es)
TW (1) TWI519533B (es)
UA (1) UA106445C2 (es)
UY (1) UY33696A (es)
WO (1) WO2012060590A2 (es)
ZA (1) ZA201302646B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007752B1 (en) 2006-03-31 2010-08-18 Janssen Pharmaceutica NV Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
MX373874B (es) 2013-03-06 2020-03-26 Janssen Pharmaceutica Nv Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
MX2023004218A (es) * 2020-10-13 2023-04-21 Lg Chemical Ltd Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma.
KR20250137744A (ko) 2024-03-11 2025-09-19 엠에프씨 주식회사 제미글립틴의 신규 결정형 및 이의 제조방법
KR20250147756A (ko) 2024-03-27 2025-10-14 엠에프씨 주식회사 신규한 형태의 제미글립틴 말산염 결정형 및 이의 제조방법
KR20250155700A (ko) 2024-04-24 2025-10-31 주식회사 다산제약 제미글립틴 산부가염 제조방법 및 이를 유효성분으로 포함하는 dpp-4 저해용 조성물
KR20260014098A (ko) 2024-07-23 2026-01-30 동방에프티엘(주) 피리도[3,4-d]피리미딘 치환된 피페리딘-2-온 유도체의 안정한 염 형태 및 이의 제조방법
CN119285630B (zh) * 2024-09-05 2025-05-27 安徽峆一药业股份有限公司 一种吉格列汀草酸盐及其晶型、制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251869A1 (en) * 2002-07-15 2004-02-02 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
JP2006516573A (ja) * 2003-01-31 2006-07-06 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth

Also Published As

Publication number Publication date
WO2012060590A2 (en) 2012-05-10
AP2013006866A0 (en) 2013-05-31
KR101446789B1 (ko) 2014-10-01
MA34625B1 (fr) 2013-10-02
US20130203787A1 (en) 2013-08-08
PH12013500685A1 (en) 2015-10-02
MX2013004776A (es) 2013-11-04
CN103189375B (zh) 2016-08-10
ECSP13012599A (es) 2013-07-31
EP2635580A2 (en) 2013-09-11
CL2013001137A1 (es) 2013-09-06
CN103189375A (zh) 2013-07-03
PE20180464A1 (es) 2018-03-06
ZA201302646B (en) 2014-01-29
CO6710945A2 (es) 2013-07-15
BR112013010586A2 (pt) 2016-08-09
AR083591A1 (es) 2013-03-06
CA2814357A1 (en) 2012-05-10
MX341584B (es) 2016-08-25
EA024679B1 (ru) 2016-10-31
US8859567B2 (en) 2014-10-14
GEP20156218B (en) 2015-01-12
TWI519533B (zh) 2016-02-01
NZ609644A (en) 2016-02-26
JP2013540810A (ja) 2013-11-07
WO2012060590A3 (en) 2012-06-28
PE20240220A1 (es) 2024-02-16
MY156428A (en) 2016-02-26
AU2011324253A1 (en) 2013-05-02
UA106445C2 (ru) 2014-08-26
IL225808A0 (en) 2013-06-27
AP3287A (en) 2015-05-31
SG189931A1 (en) 2013-06-28
TW201245189A (en) 2012-11-16
UY33696A (es) 2012-04-30
AU2011324253B2 (en) 2015-10-29
CA2814357C (en) 2015-07-07
EP2635580B1 (en) 2015-08-12
EP2635580A4 (en) 2014-04-02
IL225808A (en) 2016-08-31
EA201390644A1 (ru) 2014-11-28
KR20120046069A (ko) 2012-05-09
JP6193762B2 (ja) 2017-09-06
PE20140392A1 (es) 2014-03-22

Similar Documents

Publication Publication Date Title
DOP2013000090A (es) “HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-{2,4- BIS(TRIFUOROMETIL)-5,8-DI-HIDROPIRIDO{3,4-d} PIRIMIDIN-7 (6H)-IL}-4-OXOBUTIL}-5,5-DIFLUORO-PIRIDIN-2-ONA”
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
UY33801A (es) COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
ECSP11011526A (es) Aril-piridinas como inhibidoras de sintasa de aldosterona
CU24272B1 (es) Derivados de tetrahidropirido-pirimidina como inhibidores de mek
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
MX2013011781A (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
BR112014011055A2 (pt) novos derivados de [1,2,3]triazolo[4,5-d]pirimidina
UY32296A (es) Nuevos compuestos
MY183312A (en) Pharmaceutical formulation
DOP2011000260A (es) Pirimidinas fusionadas
UA109037C2 (uk) Триазолопіридини
PH12014500499A1 (en) Triazolopyridine compounds as pde10a inhibitors
PH12014502294A1 (en) Triazolo compounds as pde10 inhibitors
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
BR112012019866A8 (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
CO6541577A2 (es) Nuevas formas polimorfas de {4.6- diamino -2-[1-(2-fluorobencil)-1h- pirazolo[3.4-b]piridin-3il] pirimidin -5il} carbamato de metilo
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
CR20110023A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
TN2013000161A1 (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate